{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:18:32Z","timestamp":1761718712797},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12933-018-0773-1","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T08:33:41Z","timestamp":1538037221000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Satoshi","family":"Ida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"773_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","volume":"332","author":"R Huxley","year":"2006","unstructured":"Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73\u20138.","journal-title":"BMJ"},{"key":"773_CR2","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.amjcard.2017.05.014","volume":"120","author":"M Lehrke","year":"2017","unstructured":"Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120:S37\u201347.","journal-title":"Am J Cardiol"},{"key":"773_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","volume":"27","author":"SJ Pocock","year":"2006","unstructured":"Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65\u201375.","journal-title":"Eur Heart J"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.amjcard.2008.02.082","volume":"101","author":"K Eguchi","year":"2008","unstructured":"Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco RL, Homma S, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008;101:1787\u201391.","journal-title":"Am J Cardiol"},{"key":"773_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-017-0557-z","volume":"16","author":"M Kozakova","year":"2017","unstructured":"Kozakova M, Morizzo C, Fraser AG, Palombo C. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16:78.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR6","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00125-005-1896-y","volume":"48","author":"A Dawson","year":"2005","unstructured":"Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia. 2005;48:1971\u20139.","journal-title":"Diabetologia"},{"key":"773_CR7","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1161\/01.CIR.0000072789.89096.10","volume":"107","author":"M Scheuermann-Freestone","year":"2003","unstructured":"Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040\u20136.","journal-title":"Circulation"},{"key":"773_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/ehjci\/jeu142","volume":"15","author":"AM Larghat","year":"2014","unstructured":"Larghat AM, Swoboda PP, Biglands JD, Kearney MT, Greenwood JP, Plein S. The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2014;15:1368\u201376.","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"773_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00004872-200018060-00002","volume":"18","author":"NS Dhalla","year":"2000","unstructured":"Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655\u201373.","journal-title":"J Hypertens"},{"key":"773_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-105-2-173","volume":"105","author":"PN Casale","year":"1986","unstructured":"Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173\u20138.","journal-title":"Ann Intern Med"},{"key":"773_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0002-9149(01)01460-6","volume":"87","author":"JM Gardin","year":"2001","unstructured":"Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol. 2001;87:1051\u20137.","journal-title":"Am J Cardiol"},{"key":"773_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41598-018-19229-w","volume":"8","author":"JP Seferovic","year":"2018","unstructured":"Seferovic JP, Tesic M, Seferovic PM, Lalic K, Jotic A, Biering-Sorensen T, et al. Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease. Sci Rep. 2018;8:926.","journal-title":"Sci Rep."},{"key":"773_CR13","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1530\/EJE-17-0724","volume":"178","author":"E Levelt","year":"2018","unstructured":"Levelt E, Gulsin G, Neubauer S, McCann GP. Mechanisms in endocrinology: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol. 2018;178:R127\u201339.","journal-title":"Eur J Endocrinol"},{"key":"773_CR14","doi-asserted-by":"publisher","first-page":"H608","DOI":"10.1152\/ajpheart.00516.2006","volume":"292","author":"TM Lee","year":"2007","unstructured":"Lee TM, Lin MS, Tsai CH, Huang CL, Chang NC. Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients. Am J Physiol Heart Circ Physiol. 2007;292:H608\u201313.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"773_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1475-2840-8-15","volume":"8","author":"M Dorkhan","year":"2009","unstructured":"Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8:15.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1475-2840-13-43","volume":"13","author":"T Miyoshi","year":"2014","unstructured":"Miyoshi T, Nakamura K, Yoshida M, Miura D, Oe H, Akagi S, et al. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol. 2014;13:43.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-017-0546-2","volume":"16","author":"H Yamada","year":"2017","unstructured":"Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16:63.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-015-0242-z","volume":"14","author":"H Oe","year":"2015","unstructured":"Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR19","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.108.803916","volume":"119","author":"RW Meer van der","year":"2009","unstructured":"van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119:2069\u201377.","journal-title":"Circulation"},{"key":"773_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1191\/1740774505cn087oa","volume":"2","author":"MC Simmonds","year":"2005","unstructured":"Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209\u201317.","journal-title":"Clin Trials."},{"key":"773_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","volume":"313","author":"DG Altman","year":"1996","unstructured":"Altman DG, Bland JM. Detecting skewness from summary information. BMJ. 1996;313:1200.","journal-title":"BMJ"},{"key":"773_CR22","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011 (article online). \n                    http:\/\/www.cochrane-handbook.org\n                    \n                  . Accessed 1 Jan 2018."},{"key":"773_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/0962280211432219","volume":"22","author":"D Mavridis","year":"2013","unstructured":"Mavridis D, Salanti G. A practical introduction to multivariate meta-analysis. Stat Methods Med Res. 2013;22:133\u201358.","journal-title":"Stat Methods Med Res"},{"key":"773_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/bimj.201200152","volume":"55","author":"D Jackson","year":"2013","unstructured":"Jackson D, White IR, Riley RD. A matrix-based method of moments for fitting the multivariate random effects model for meta-analysis and meta-regression. Biom J. 2013;55:231\u201345.","journal-title":"Biom J."},{"key":"773_CR25","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8:e76654.","journal-title":"PLoS ONE"},{"key":"773_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jrsm.1188","volume":"7","author":"D Jackson","year":"2016","unstructured":"Jackson D, Boddington P, White IR. The design-by-treatment interaction model: a unifying framework for modelling loop inconsistency in network meta-analysis. Res Synth Methods. 2016;7:329\u201332.","journal-title":"Res Synth Methods."},{"key":"773_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1479164111428628","volume":"9","author":"J McGavock","year":"2012","unstructured":"McGavock J, Szczepaniak LS, Ayers CR, Abdullah SM, See R, Gore MO, et al. The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial. Diab Vasc Dis Res. 2012;9:131\u20137.","journal-title":"Diab Vasc Dis Res."},{"key":"773_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1475-2840-9-57","volume":"9","author":"KK Naka","year":"2010","unstructured":"Naka KK, Pappas K, Papathanassiou K, Papamichael ND, Kazakos N, Kanioglou C, et al. Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. Cardiovasc Diabetol. 2010;9:57.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR29","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/eurheartj\/ehq228","volume":"31","author":"DK McGuire","year":"2010","unstructured":"McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, et al. Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur Heart J. 2010;31:2262\u201370.","journal-title":"Eur Heart J"},{"key":"773_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1540-8175.2009.01083.x","volume":"27","author":"S Pala","year":"2010","unstructured":"Pala S, Esen O, Akcakoyun M, Kahveci G, Kargin R, Tigen K, et al. Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study. Echocardiography. 2010;27:512\u20138.","journal-title":"Echocardiography."},{"key":"773_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cardfail.2008.02.007","volume":"14","author":"TD Giles","year":"2008","unstructured":"Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14:445\u201352.","journal-title":"J Card Fail."},{"key":"773_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.diabres.2006.03.009","volume":"74","author":"NH Pan","year":"2006","unstructured":"Pan NH, Lee TM, Lin MS, Huang CL, Chang NC. Association of gliclazide and left ventricular mass in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;74:121\u20138.","journal-title":"Diabetes Res Clin Pract"},{"key":"773_CR33","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.2337\/diacare.25.11.2058","volume":"25","author":"M St John Sutton","year":"2002","unstructured":"St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:2058\u201364.","journal-title":"Diabetes Care"},{"key":"773_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/pedi.12119","volume":"16","author":"L Levitt Katz","year":"2015","unstructured":"Levitt Katz L, Gidding SS, Bacha F, Hirst K, McKay S, Pyle L, et al. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. Pediatric Diabetes. 2015;16:39\u201347.","journal-title":"Pediatric Diabetes."},{"key":"773_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12933-017-0632-5","volume":"16","author":"M Suto","year":"2017","unstructured":"Suto M, Tanaka H, Mochizuki Y, Mukai J, Takada H, Soga F, et al. Impact of overweight on left ventricular function in type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16:145.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12933-017-0519-5","volume":"16","author":"J Park","year":"2017","unstructured":"Park J, Kim J, Kim SH, Kim S, Lim SY, Lim H, et al. Subclinical left ventricular diastolic dysfunction and incident type 2 diabetes risk: the Korean Genome and Epidemiology Study. Cardiovasc Diabetol. 2017;16:36.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR37","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","volume":"322","author":"D Levy","year":"1990","unstructured":"Levy D. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561\u20136.","journal-title":"N Engl J Med"},{"key":"773_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0140-6736(85)90403-9","volume":"2","author":"NC Sturgess","year":"1985","unstructured":"Sturgess NC, Ashford ML, Cook DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet. 1985;2:474\u20135.","journal-title":"Lancet"},{"key":"773_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/meta.2000.17825","volume":"49","author":"PE Jennings","year":"2000","unstructured":"Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism. 2000;49:17\u201320.","journal-title":"Metabolism."},{"key":"773_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.numecd.2008.12.009","volume":"19","author":"E Gerdts","year":"2009","unstructured":"Gerdts E, Okin PM, Omvik P, Wachtell K, Dahlof B, Hildebrandt P, et al. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr Metab Cardiovasc Dis. 2009;19:306\u201312.","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"773_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-017-0504-z","volume":"16","author":"KA Jong De","year":"2017","unstructured":"De Jong KA, Czeczor JK, Sithara S, McEwen K, Lopaschuk GD, Appelbe A, et al. Obesity and type 2 diabetes have additive effects on left ventricular remodeling in normotensive patients-a cross sectional study. Cardiovasc Diabetol. 2017;16:21.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR42","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s001250100595","volume":"44","author":"CL Lawrence","year":"2001","unstructured":"Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, et al. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001;44:1019\u201325.","journal-title":"Diabetologia"},{"key":"773_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00592-007-0014-7","volume":"45","author":"C Sambanis","year":"2008","unstructured":"Sambanis C, Tziomalos K, Kountana E, Kakavas N, Zografou I, Balaska A, et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol. 2008;45:23\u201330.","journal-title":"Acta Diabetol"},{"key":"773_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-017-0544-4","volume":"16","author":"AR Aroor","year":"2017","unstructured":"Aroor AR, Habibi J, Kandikattu HK, Garro-Kacher M, Barron B, Chen D, et al. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. Cardiovasc Diabetol. 2017;16:1\u201315.","journal-title":"Cardiovasc Diabetol."},{"key":"773_CR45","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/1744-9987.12319","volume":"19","author":"T Hiramatsu","year":"2015","unstructured":"Hiramatsu T, Ozeki A, Asai K, Saka M, Hobo A, Furuta S. Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis. Ther Apher Dial. 2015;19:598\u2013605.","journal-title":"Ther Apher Dial."},{"key":"773_CR46","doi-asserted-by":"publisher","first-page":"e0183664","DOI":"10.1371\/journal.pone.0183664","volume":"12","author":"NA Hesen","year":"2017","unstructured":"Hesen NA, Riksen NP, Aalders B, Ritskes-Hoitinga M, El Messaoudi S, Wever KE. A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction. PLoS ONE. 2017;12:e0183664.","journal-title":"PLoS ONE"},{"key":"773_CR47","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"773_CR48","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","volume":"32","author":"TK Schramm","year":"2011","unstructured":"Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900\u20138.","journal-title":"Eur Heart J"},{"key":"773_CR49","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"773_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9.","journal-title":"Cardiovasc Diabetol."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-018-0773-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T23:42:40Z","timestamp":1569541360000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0773-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"14 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"129"}}